Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer

Journal of Korean Neurosurgical Society

Volumn 58, Issue 3, 2015, Pages 205-210

  Kim, Hyun Jung ^a   Kim, Woo Sung ^a   Kwon, Do Hoon ^a   Cho, Young Hyun ^a   Choi, Chang Min ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Carcinoma; Epiderrmal growth factor; Neoplasm metastasis; Non small cell lung; Radiosurgery

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; MALE; MUTATION; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY;

EID: 84944077549     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2015.58.3.205     Document Type: Article

References (27)

1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295: 2483-2491, 2006
2. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15: 1042-1047, 2004
3. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99: 283-286, 2010
4. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al.: “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13: 1364-1369, 2011
5. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al.: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16: 5873-5882, 2010
6. Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, et al.: Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46: 255-261, 2004
7. Kim HS, Koh EJ, Choi HY: Multiple gamma knife radiosurgery for multiple metachronous brain metastases associated with lung cancer: survival time. J Korean Neurosurg Soc 52: 334-338, 2012
8. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS: Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50: 265-269, 2005
9. Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al.: Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75: 82-88, 2012
10. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al.: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29: 134-141, 2011
11. Kuiper JL, Smit EF: High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well. Lung Cancer 80: 102-105, 2013
12. Langer CJ, Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23: 6207-6219, 2005
13. Ma S, Xu Y, Deng Q, Yu X: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65: 198-203, 2009
14. Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Lanzetta G, et al.: Stereotactic radiosurgery in elderly patients with brain metastases. J Neurooncol 111: 319-325, 2013
15. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005
16. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010
17. Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, et al.: Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6: 123-128, 2004
18. National Comprehensive Cancer Network I: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Non-Small Cell lung cancer. Washington DC: National Comprehensive Cancer Network, 2014
19. Park BJ, Lim YJ, Kim TS, Rhee BA, Leem W, Kim GK: Brain metastasis from lung cancer-treatment and prognosis-. J Korean Neurosurg Soc 27: 53-58, 1998
20. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al.: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77: 556-560, 2012
21. Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, et al.: Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37: 624-631, 2011
22. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD: Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97: 1276-1281, 2002
23. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014
24. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837, 2005
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000
26. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, et al.: Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 31: 256-273, 2005
27. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al.: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31: 895-902, 2013